439 related articles for article (PubMed ID: 33407869)
1. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
2. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
[TBL] [Abstract][Full Text] [Related]
7. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
[TBL] [Abstract][Full Text] [Related]
8. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
Langton D; Politis J; Collyer T; Khung SW; Bardin P
Respirology; 2023 Dec; 28(12):1117-1125. PubMed ID: 37638723
[TBL] [Abstract][Full Text] [Related]
12. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
13. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
14. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
[TBL] [Abstract][Full Text] [Related]
15. [The Effectiveness of Mepolizumab and Benralizumab in a Real-Life Cohort of Patients with Severe Eosinophilic Asthma].
Espinosa de Los Monteros Garde MJ; Romero Sanz V; Blázquez Romero C
Open Respir Arch; 2021; 3(2):100103. PubMed ID: 37497072
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
AlShareef S; McDonald CF; Lee J
J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
[TBL] [Abstract][Full Text] [Related]
17. Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.
Calzetta L; Ritondo BL; Matera MG; Facciolo F; Rogliani P
Br J Pharmacol; 2020 Oct; 177(20):4750-4765. PubMed ID: 32857420
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
19. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
[TBL] [Abstract][Full Text] [Related]
20. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]